CJC-1295 DAC (Peptides) : The Long Acting Growth Hormone Stimulator, Pituitary Amplifier, Anabolic Research Peptide

CJC-1295 DAC is a synthetic peptide engineered for sustained activation of the growth hormone axis. By binding to blood albumin, this modified growth hormone releasing hormone analog creates prolonged elevation of GH and IGF 1 levels, distinguishing it sharply from short acting peptides that mimic the body's natural pulsatile rhythm.

---

1. Overview:

CJC-1295 DAC is a synthetic analog of growth hormone releasing hormone (GHRH), comprising 29 amino acids. Its defining feature is the Drug Affinity Complex (DAC), a bioconjugation technology that allows the peptide to bind covalently to endogenous albumin in the bloodstream. This albumin binding dramatically extends the compound's half life to approximately 6 to 8 days, creating sustained stimulation of the anterior pituitary gland. Unlike short acting GHRH analogs that produce brief pulses of growth hormone, CJC-1295 DAC elevates both the baseline (trough) and peak levels of GH while preserving the natural pulsatile pattern of secretion .

2. Origin & Common Forms:

The compound was developed in the mid-2000s by ConjuChem Technologies, initially intended for research into conditions such as HIV associated lipodystrophy and growth hormone deficiency. The standard form contains the DAC modification, though market confusion has led to two distinct versions being available.

3. Common Supplemental Forms: Standard & Enhanced

The supplemental market offers two distinct forms with fundamentally different pharmacokinetics.

· CJC-1295 with DAC: The original long acting version. The DAC component binds to albumin, extending half life to approximately 6 to 8 days. A single injection produces sustained elevation of GH and IGF 1 lasting up to 14 days. This form is associated with a steady "bleed" of GH rather than discrete pulses.

· CJC-1295 without DAC (Modified GRF 1 29): A short acting version with a half life of approximately 30 minutes. It produces a sharp, brief pulse of GH that more closely mimics the body's natural secretory rhythm. This form is often used in research combinations with growth hormone releasing peptides like Ipamorelin to create a strong synergistic pulse.

· Combination Products (CJC-1295 / Ipamorelin): A popular blend in research settings. CJC-1295 acts as a GHRH analog while Ipamorelin functions as a ghrelin mimetic. Together they target two different receptors on the pituitary, producing a more robust GH release than either compound alone .

4. Natural Origin:

CJC-1295 DAC does not occur in nature. It is a fully synthetic peptide modeled on the structure of endogenous GHRH, a 44 amino acid hormone produced by the hypothalamus. The natural hormone has a half life of only a few minutes, making it unsuitable for sustained research applications.

5. Synthetic / Man-made:

The compound is produced entirely through solid phase peptide synthesis (SPPS). This chemical process assembles the 29 amino acid chain step by step. The DAC component, a lysine derivative, is incorporated during synthesis to enable albumin binding. For research purposes, the peptide is typically supplied as an acetate salt.

6. Commercial Production:

· Precursors: Protected amino acids and specialized reagents for peptide synthesis.

· Process: Automated solid phase synthesis, cleavage from the resin, purification via high performance liquid chromatography (HPLC), and lyophilization to a white powder. Quality control includes mass spectrometry verification and purity analysis, typically targeting >95% purity.

· Purity & Efficacy: Research grade material is standardized by purity percentage and mass (e.g., 5 mg vials). Efficacy is measured by the compound's ability to elevate GH and IGF 1 in experimental models. The presence of DAC is confirmed by the peptide's extended duration of action .

7. Key Considerations:

The DAC Distinction. The presence or absence of the Drug Affinity Complex fundamentally alters the compound's behavior and research applications. CJC-1295 with DAC creates a sustained, week long elevation of GH and IGF 1. This is useful for studying the effects of chronic GH axis stimulation but raises distinct safety considerations regarding prolonged exposure. The version without DAC is preferred when researchers wish to study pulsatile GH release or avoid persistent elevation of baseline hormone levels .

8. Structural Similarity:

A 29 amino acid peptide that mimics the bioactive portion of endogenous GHRH. The DAC modification involves a lysine derivative that enables covalent bonding to serum albumin. This albumin binding is the structural feature responsible for the extended half life.

9. Biofriendliness:

· Utilization: After subcutaneous injection, the peptide binds to circulating albumin. This binding protects it from rapid enzymatic degradation and renal clearance. The albumin bound complex gradually releases active peptide, providing sustained stimulation of pituitary somatotroph cells.

· Metabolism & Excretion: The compound is cleared slowly over approximately 8 days. The exact metabolic pathway involves proteolytic degradation of the peptide backbone. The DAC albumin complex is eventually processed through normal protein clearance mechanisms.

· Toxicity: Acute toxicity data is limited to material safety data sheets, which classify the compound as harmful if swallowed and very toxic to aquatic life. Long term toxicity in humans has not been systematically studied .

10. Known Benefits (Clinically Supported):

Human clinical data on CJC-1295 DAC comes primarily from a small number of phase I studies conducted in the mid-2000s.

· Sustained GH and IGF 1 Elevation: A landmark 2006 study by Teichman et al. demonstrated that a single subcutaneous injection of CJC-1295 DAC produced dose dependent and prolonged increases in both GH and IGF 1 levels in healthy young men. The effects lasted up to 14 days.

· Preserved Pulsatility with Elevated Baseline: Research by Ionescu and Frohman showed that CJC-1295 DAC increases both the trough (baseline) and peak levels of GH while preserving the natural pulsatile pattern of secretion. The trough levels increased 7.5 fold, contributing to an overall 46% increase in mean GH levels and a 45% increase in IGF 1 .

· GH Pulse Mass Augmentation: The compound increases the amount of GH secreted per pulse without altering pulse frequency. This distinguishes it from continuous GH infusion, which can suppress endogenous pulsatility.

11. Purported Mechanisms:

· GHRH Receptor Agonism: The peptide binds to and activates GHRH receptors on pituitary somatotroph cells, stimulating the synthesis and secretion of growth hormone.

· Albumin Binding (DAC Mechanism): The covalent binding to serum albumin prevents rapid clearance, transforming a molecule with a native half life of minutes into one that persists for over a week. This creates continuous receptor stimulation.

· IGF 1 Generation: The increased GH secretion stimulates hepatic and peripheral production of insulin like growth factor 1 (IGF 1), which mediates many of the anabolic and metabolic effects attributed to GH.

· mTOR Pathway Activation: In research models, the resulting elevation of GH and IGF 1 activates the mTOR signaling pathway, a critical regulator of protein synthesis and cellular growth .

12. Other Possible Benefits Under Research:

· Investigation in cellular aging and age related decline. Researchers have proposed that restoring GH and IGF 1 to more youthful profiles may provide insights into mitigating age related physiological changes .

· Exploration of metabolic effects including lipolysis and fat oxidation, making the compound of interest in obesity and metabolic syndrome research.

· Potential neuroprotective applications, as GH and IGF 1 play roles in neuronal health and repair.

· Wound healing and tissue repair studies, leveraging the anabolic properties of GH.

13. Side Effects:

Reported adverse events from human studies and user reports include:

· Minor & Transient: Injection site reactions (redness, pain, swelling), headaches, mild diarrhea, flu like symptoms.

· Moderate & Dose Dependent: Water retention, joint pain, carpal tunnel like symptoms (tingling in hands), lethargy.

· Serious & Rare: One fatality occurred during early clinical development, though the attending physician concluded the cause was not directly attributable to CJC-1295 administration .

· Metabolic Concerns: Long term elevation of GH and IGF 1 can impair insulin sensitivity and raise fasting blood glucose. Studies on related GH secretagogues have demonstrated these effects over extended treatment periods.

· To Be Cautious About: The extremely long half life means that once administered, the compound cannot be quickly removed if adverse effects occur. This makes dose titration and monitoring particularly important.

14. Dosing & How to Take:

Dosing is highly dependent on the specific form and research protocol. The following ranges are derived from clinical studies and research guidelines.

· CJC-1295 with DAC (Long Acting): Clinical studies used single doses of 60 or 90 micrograms per kilogram of body weight. Research protocols typically employ 1 to 2 milligrams subcutaneously, once weekly. The long half life allows for convenient weekly administration .

· CJC-1295 without DAC (Short Acting): The standard dose is 100 micrograms subcutaneously, taken 1 to 3 times daily. Common schedules include once before bed, or morning and bedtime. This form requires more frequent administration.

· Combination with Ipamorelin: Typical combined dose is 100 to 200 micrograms of CJC-1295 plus 100 to 200 micrograms of Ipamorelin, once daily before bed on an empty stomach .

· Cycle Length: Research cycles typically run 8 to 12 weeks, followed by a 2 to 4 week washout period to allow hormone levels to normalize. Extended protocols may repeat this pattern under medical supervision .

· How to Take: Subcutaneous injection into abdominal fat tissue using an insulin syringe. The peptide is reconstituted from lyophilized powder using bacteriostatic water. For the without DAC form, administration on an empty stomach (2 to 3 hours after last meal) is critical, and food should be avoided for 30 minutes after injection to prevent insulin spikes that blunt GH release.

15. Tips to Optimize Benefits:

· Form Selection: Choose the DAC or non DAC version based on research objectives. DAC provides sustained, week long elevation ideal for studying chronic effects. Non DAC provides discrete pulses that better mimic natural physiology and allow for faster washout.

· Timing (Short Acting Form): Administration before bed aligns with the body's natural nocturnal GH pulse and leverages the overnight fasting state to maximize lipolytic effects.

· Synergistic Combinations: Pairing CJC-1295 (a GHRH analog) with a GHRP like Ipamorelin creates a synergistic effect on GH release, as the two compounds activate distinct receptors on the pituitary .

· Monitoring: Regular assessment of IGF 1 levels, fasting glucose, and HbA1c is essential during extended research protocols to detect metabolic derangements early.

· Lifestyle Factors: The effects of GH axis stimulation are amplified by adequate protein intake, resistance training, and sufficient sleep. These factors should be controlled for in research settings.

16. Not to Exceed / Warning / Interactions:

· Drug Interactions: Use with caution alongside medications that affect glucose metabolism (insulin, oral hypoglycemics) as additive hyperglycemic effects may occur. Concurrent use with other GH secretagogues may produce excessive GH elevation.

· Medical Conditions: The compound is contraindicated in individuals with active malignancy, as GH and IGF 1 are mitogenic. Caution is required in those with diabetes, impaired glucose tolerance, or a family history of acromegaly. Pituitary tumors or structural abnormalities affecting the sella turcica are absolute contraindications.

· Regulatory Status: CJC-1295 is classified under Section S2 of the World Anti Doping Agency (WADA) Prohibited List as a prohibited substance at all times. There are currently no FDA approved products containing CJC-1295, and it is classed as an Investigational New Drug available exclusively for research purposes .

17. LD50 & Safety:

· Acute Toxicity (LD50): Not established in humans. Material safety data sheets classify the compound as Acute Toxicity Category 4 (Harmful if swallowed) based on oral exposure risk .

· Human Safety: Short term studies (single dose and up to 26 weeks) indicate a generally tolerable safety profile. However, long term safety data is lacking. The primary safety concerns relate to metabolic effects (insulin resistance, glucose intolerance), fluid retention, and the theoretical risk of neoplasia due to prolonged IGF 1 elevation.

· Environmental Hazard: The compound is classified as very toxic to aquatic life with long lasting effects. It should not be disposed of in household waste or wastewater .

18. Consumer Guidance:

· Label Literacy: The label must specify "CJC-1295 with DAC" or "CJC-1295 DAC." Vials are typically supplied as lyophilized powder measured in milligrams (e.g., 2 mg, 5 mg). Confirm the presence of DAC if a long acting profile is desired. Products labeled "CJC-1295 no DAC" or "Mod GRF 1-29" are the short acting version.

· Quality Assurance: For research use, select suppliers that provide Certificates of Analysis (CoA) confirming peptide purity (>95%) and mass spectrometry verification. The peptide should be stored lyophilized at 20°C and reconstituted immediately before use.

· Regulatory Compliance: This compound is not approved for human consumption as a dietary supplement or therapeutic. It is strictly a research chemical. Possession and use outside of authorized research settings may be subject to legal restrictions depending on jurisdiction.

· Manage Expectations: Unlike short acting GHRH analogs that produce brief, pulse like stimulation, CJC-1295 DAC creates sustained elevation of GH and IGF 1. This profile is fundamentally different from the body's natural rhythm. Research protocols should account for this distinction when designing experiments and interpreting results. The compound is not a "quick fix" but a tool for studying sustained GH axis activation and its downstream metabolic and anabolic effects .